EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Westaby, S.
Right arrow Articles by Pillai, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westaby, S.
Right arrow Articles by Pillai, R.

European Journal of Cardio-Thoracic Surgery, Vol 8, 82-86, Copyright © 1994 by European Association for Cardio-thoracic Surgery

ARTICLES

Aprotinin and bleeding in profoundly hypothermic perfusion

S Westaby, A Forni, J Dunning, N Giannopoulos, D O'Regan, G Drossos and R Pillai
Oxford Heart Centre, John Radcliffe Hospital, UK.

Clinical observation led us to believe that aprotinin fails to preserve haemostatic function in patients undergoing deep hypothermic perfusion with or without circulatory arrest. A retrospective study was made of blood loss in 80 consecutive acute Type A dissection patients before and during the aprotinin era (1987-1992). After 1988 all patients were cooled below 20 degrees C pending circulatory arrest. Fourteen patients underwent aortic root replacement and 66 replacements of the ascending aorta. Age distribution (range 22-79 years) and type of operation were similar in the aprotinin and control groups. The impervious Hemashield (Meadox) graft was used for all but five patients. These underwent aortic root replacement with preclotted, valved conduits. Overall the mean blood loss for 27 patients operated without aprotinin was 837 ml per 24 h (standard error +/- 90) and for 53 patients with aprotinin 1,929 ml per 24 h (standard error +/- 90). There was a significant difference between the two groups when profoundly hypothermic perfusion was used, with greater bleeding in aprotinin-treated patients. There were six re-entries in the aprotinin group and none in the control patients. There were ten hospital deaths (11.1%). A greater incidence of bleeding and thrombosis-related deaths was recorded for the aprotinin-treated patients. In addition, four surviving aprotinin patients suffered severe coagulation defect with blood loss greater than 4,500 ml and platelets less than 50 x 10(6). We suggest that aprotinin inhibits the protease enzymes which maintain the fluid state of blood during hypothermic low flow and arrest states. Disseminated intravascular coagulation may consume platelets thereby predisposing to abnormal bleeding and potentially fatal thrombotic events. The use of aprotinin in profoundly hypothermic perfusion should be adopted cautiously.


This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
S. Westaby
Aprotinin: Twenty-five years of claim and counterclaim
J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 487 - 491.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Sedrakyan, A. Wu, G. Sedrakyan, M. Diener-West, M. Tranquilli, and J. Elefteriades
Aprotinin use in thoracic aortic surgery: Safety and outcomes
J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 909 - 917.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
V. Casati, L. Sandrelli, G. Speziali, G. Calori, M. A. Grasso, and S. Spagnolo
Hemostatic effects of tranexamic acid in elective thoracic aortic surgery: A prospective, randomized, double-blind, placebo-controlled study
J. Thorac. Cardiovasc. Surg., June 1, 2002; 123(6): 1084 - 1091.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. Westaby, S. Saito, and T. Katsumata
Acute type A dissection: conservative methods provide consistently low mortality
Ann. Thorac. Surg., March 1, 2002; 73(3): 707 - 713.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr
Mechanisms and attenuation of hemostatic activation during extracorporeal circulation
Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. T. Mora Mangano, M. J. Neville, P. H. Hsu, I. Mignea, J. King, and D. C. Miller
Aprotinin, Blood Loss, and Renal Dysfunction in Deep Hypothermic Circulatory Arrest
Circulation, September 18, 2001; 104(90001): I-276 - 281.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. R. Smith and T. B. Spanier
Aprotinin in deep hypothermic circulatory arrest
Ann. Thorac. Surg., July 1, 1999; 68(1): 278 - 286.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. Westaby
Anti-fibrinolytic therapy in thoracic aortic surgery
Ann. Thorac. Surg., June 1, 1999; 67(6): 1983 - 1985.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. G.H. Speekenbrink, R. M. Bertina, F. Espana, C. R.H. Wildevuur, and L. Eijsman
Activation of the protein C system during cardiopulmonary bypass with and without aprotinin
Ann. Thorac. Surg., December 1, 1998; 66(6): 1998 - 2002.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
P. Pouard
Review of Efficacy Parameters
Ann. Thorac. Surg., June 1, 1998; 65(90060): S40 - 44.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. M. Alvarez, J. Goldstein, J. Mezzatesta, B. Flanagan, and M. Dodd
Fatal intraoperative pulmonary thrombosis after graft replacement ofan aneurysm of the arch and descending aorta in association with deephypothermic circulatory arrest and aprotinin therapy
J. Thorac. Cardiovasc. Surg., March 1, 1998; 115(3): 723 - 724.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Ehrlich, M. Grabenwoger, F. Cartes-Zumelzu, D. Luckner, J. Kovarik, G. Laufer, A. Kocher, R. Konetschny, E. Wolner, and M. Havel
Operations on the thoracic aorta and hypothermic circulatory arrest: Is aprotinin safe?
J. Thorac. Cardiovasc. Surg., January 1, 1998; 115(1): 220 - 224.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
S. Westaby
Aprotinin Fifteen Years Later
Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 366 - 375.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. Westaby, T. Katsumata, and E. Freitas
Aortic Valve Conservation in Acute Type A Dissection
Ann. Thorac. Surg., October 1, 1997; 64(4): 1108 - 1112.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
S. Cicek, U. Demirkilic, E. Ozal, E. Kuralay, H. Bingol, H. Tatar, and O. Y. Ozturk
POSTOPERATIVE USE OF APROTININ IN CARDIAC OPERATIONS: AN ALTERNATIVE TO ITS PROPHYLACTIC USE
J. Thorac. Cardiovasc. Surg., December 1, 1996; 112(6): 1462 - 1467.
[Abstract] [Full Text]

Home page
 Ann. Thorac. Surg.Home page
S. Cicek, U. Demirkilic, E. Kuralay, E. Ozal, and H. Tatar
Postoperative Aprotinin: Effect on Blood Loss and Transfusion Requirements in Cardiac Operations
Ann. Thorac. Surg., May 1, 1996; 61(5): 1372 - 1376.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. J. Goldstein, C. M. DeRosa, L. B. Mongero, A. D. Weinberg, R. E. Michler, E. A. Rose, M. C. Oz, and C. R. Smith
SAFETY AND EFFICACY OF APROTININ UNDER CONDITIONS OF DEEP HYPOTHERMIA AND CIRCULATORY ARREST
J. Thorac. Cardiovasc. Surg., December 1, 1995; 110(6): 1615 - 1622.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1994 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.